Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus BCMC 12130
- Development stage
- Preclinical
- Lead developer
- B-Crobes
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
Lactobacillus acidophilus BCMC 12130 is a specific probiotic bacterial strain developed by B-Crobes Laboratories Sdn. Bhd. It is a live microorganism biologic intended for oral administration. While it is one of six strains included in the multi-strain probiotic product HEXBIO, it has distinct mechanisms. One such mechanism is the production of the Bile Salt Hydrolase (BSH) enzyme, which modulates bile acids to increase colonic water secretion and stimulate gut motility. As part of HEXBIO, it has been clinically evaluated for its immunomodulatory effects, particularly its ability to reduce pro-inflammatory cytokines like TNF-α and various interleukins in post-surgical colorectal cancer patients. Studies also suggest its potential use in managing constipation in Parkinson's disease, primary dysmenorrhea, and metabolic parameters in overweight individuals.
- Other names
- Lactobacillus acidophilus BCMC® 12130L. acidophilus BCMC 12130
02
Targets
IL10 (Interleukin-10)IL17C (IL-17C)TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)IL-17A (Interleukin-17A)IL12 (Interleukin-12)IL22 (Interleukin 22)
Beyond the preview
Go deeper on lactobacillus acidophilus BCMC 12130.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus BCMC 12130.